Kelly Maloney
Concepts (360)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 40 | 2025 | 280 | 6.020 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2024 | 75 | 1.570 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 1565 | 1.400 |
Why?
| Down Syndrome | 6 | 2023 | 470 | 1.360 |
Why?
| Burkitt Lymphoma | 3 | 2024 | 55 | 1.010 |
Why?
| Asparaginase | 8 | 2020 | 29 | 0.900 |
Why?
| Leukemia, Myeloid, Acute | 6 | 2024 | 591 | 0.810 |
Why?
| Child | 71 | 2025 | 20721 | 0.780 |
Why?
| Consolidation Chemotherapy | 2 | 2019 | 9 | 0.710 |
Why?
| Child, Preschool | 47 | 2024 | 10373 | 0.640 |
Why?
| Disease-Free Survival | 12 | 2024 | 656 | 0.600 |
Why?
| Leukemia | 4 | 2021 | 229 | 0.580 |
Why?
| Oncogene Proteins, Fusion | 6 | 2024 | 198 | 0.580 |
Why?
| Mercaptopurine | 5 | 2017 | 15 | 0.550 |
Why?
| Neoplasm Recurrence, Local | 5 | 2024 | 957 | 0.540 |
Why?
| Antineoplastic Agents | 7 | 2019 | 2058 | 0.500 |
Why?
| Prognosis | 15 | 2024 | 3780 | 0.490 |
Why?
| Preleukemia | 1 | 2015 | 2 | 0.480 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2016 | 111 | 0.480 |
Why?
| Drug Hypersensitivity | 3 | 2017 | 81 | 0.470 |
Why?
| Infant | 34 | 2024 | 8913 | 0.470 |
Why?
| Molecular Targeted Therapy | 3 | 2021 | 387 | 0.460 |
Why?
| Leukemia, Monocytic, Acute | 1 | 2014 | 3 | 0.460 |
Why?
| Sarcoma, Myeloid | 1 | 2014 | 4 | 0.450 |
Why?
| Recurrence | 11 | 2024 | 1001 | 0.450 |
Why?
| Neoplasm, Residual | 7 | 2023 | 118 | 0.430 |
Why?
| Adolescent | 40 | 2024 | 20213 | 0.410 |
Why?
| Bone Marrow Transplantation | 1 | 2014 | 268 | 0.410 |
Why?
| Medical Oncology | 5 | 2025 | 272 | 0.400 |
Why?
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 24 | 0.400 |
Why?
| Erwinia | 2 | 2020 | 3 | 0.390 |
Why?
| Humans | 83 | 2025 | 128524 | 0.380 |
Why?
| Tumor Suppressor Proteins | 3 | 1999 | 312 | 0.380 |
Why?
| Acute Kidney Injury | 1 | 2019 | 774 | 0.370 |
Why?
| Chromosome Aberrations | 2 | 2022 | 147 | 0.370 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 573 | 0.370 |
Why?
| Neutropenia | 2 | 2022 | 136 | 0.360 |
Why?
| Male | 55 | 2024 | 62883 | 0.360 |
Why?
| Stem Cell Transplantation | 3 | 2019 | 164 | 0.350 |
Why?
| Rhabdomyosarcoma | 1 | 2011 | 64 | 0.340 |
Why?
| Cell Cycle Proteins | 3 | 1999 | 580 | 0.340 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 113 | 0.340 |
Why?
| Carrier Proteins | 3 | 1999 | 731 | 0.340 |
Why?
| Sarcoma, Ewing | 1 | 2011 | 88 | 0.330 |
Why?
| Ploidies | 2 | 2019 | 17 | 0.330 |
Why?
| Catheter-Related Infections | 2 | 2022 | 68 | 0.310 |
Why?
| Survival Rate | 8 | 2024 | 1872 | 0.310 |
Why?
| Core Binding Factor Alpha 2 Subunit | 3 | 2021 | 32 | 0.310 |
Why?
| Genes, Tumor Suppressor | 2 | 1999 | 86 | 0.310 |
Why?
| Cyclophosphamide | 4 | 2019 | 231 | 0.300 |
Why?
| Female | 53 | 2024 | 68127 | 0.300 |
Why?
| Catheterization, Central Venous | 2 | 2022 | 97 | 0.300 |
Why?
| Philadelphia Chromosome | 2 | 2018 | 18 | 0.280 |
Why?
| Medication Adherence | 3 | 2017 | 573 | 0.260 |
Why?
| Gene Deletion | 2 | 1998 | 372 | 0.260 |
Why?
| Vincristine | 4 | 2021 | 110 | 0.260 |
Why?
| Trisomy | 2 | 2021 | 77 | 0.250 |
Why?
| Antimetabolites, Antineoplastic | 2 | 2017 | 90 | 0.250 |
Why?
| Neoplasm Proteins | 2 | 2018 | 421 | 0.250 |
Why?
| Etoposide | 2 | 2019 | 149 | 0.250 |
Why?
| Young Adult | 15 | 2024 | 12320 | 0.240 |
Why?
| Treatment Outcome | 12 | 2023 | 10163 | 0.230 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 1999 | 69 | 0.230 |
Why?
| Anxiety | 3 | 2016 | 949 | 0.220 |
Why?
| PAX5 Transcription Factor | 2 | 2024 | 14 | 0.220 |
Why?
| Health Equity | 1 | 2024 | 79 | 0.200 |
Why?
| Gene Rearrangement | 3 | 2019 | 145 | 0.200 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 64 | 0.200 |
Why?
| Polyethylene Glycols | 5 | 2020 | 597 | 0.200 |
Why?
| Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 3 | 0.200 |
Why?
| Induction Chemotherapy | 2 | 2019 | 70 | 0.190 |
Why?
| Central Venous Catheters | 1 | 2022 | 48 | 0.190 |
Why?
| Lymphoma | 1 | 2023 | 194 | 0.190 |
Why?
| Doxorubicin | 2 | 2022 | 322 | 0.190 |
Why?
| Adult | 23 | 2023 | 35315 | 0.180 |
Why?
| Program Evaluation | 2 | 2017 | 874 | 0.180 |
Why?
| Prednisone | 2 | 2019 | 236 | 0.180 |
Why?
| Lung Neoplasms | 1 | 2014 | 2323 | 0.180 |
Why?
| Translocation, Genetic | 2 | 2013 | 97 | 0.180 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2017 | 2065 | 0.170 |
Why?
| Maintenance Chemotherapy | 2 | 2017 | 22 | 0.170 |
Why?
| Bacterial Infections | 1 | 2022 | 227 | 0.170 |
Why?
| Genomics | 3 | 2024 | 716 | 0.170 |
Why?
| Risk Factors | 11 | 2022 | 9727 | 0.170 |
Why?
| Immunocompromised Host | 1 | 2021 | 195 | 0.170 |
Why?
| Diploidy | 1 | 2019 | 13 | 0.160 |
Why?
| Quality of Life | 3 | 2024 | 2680 | 0.160 |
Why?
| Genes, p16 | 1 | 1999 | 20 | 0.160 |
Why?
| Hyperglycemia | 1 | 2023 | 325 | 0.160 |
Why?
| Prospective Studies | 9 | 2022 | 7043 | 0.160 |
Why?
| Chromosomes, Human, Pair 19 | 1 | 1998 | 23 | 0.150 |
Why?
| Myelodysplastic Syndromes | 1 | 2020 | 129 | 0.150 |
Why?
| Antibodies, Bispecific | 1 | 2019 | 49 | 0.150 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 1998 | 54 | 0.150 |
Why?
| Rituximab | 1 | 2019 | 163 | 0.150 |
Why?
| Chromosomes, Human, Pair 1 | 1 | 1998 | 70 | 0.150 |
Why?
| Mutagenesis | 1 | 1999 | 181 | 0.150 |
Why?
| Patient Safety | 1 | 2021 | 290 | 0.150 |
Why?
| Prostate-Specific Antigen | 2 | 2009 | 160 | 0.150 |
Why?
| Substance Withdrawal Syndrome | 1 | 2020 | 171 | 0.140 |
Why?
| Proto-Oncogenes | 1 | 1997 | 29 | 0.140 |
Why?
| Family Relations | 2 | 2016 | 89 | 0.140 |
Why?
| Thioguanine | 1 | 2017 | 18 | 0.140 |
Why?
| Thionucleotides | 1 | 2017 | 34 | 0.140 |
Why?
| Oncologists | 1 | 2017 | 36 | 0.140 |
Why?
| Apyrase | 1 | 2017 | 17 | 0.140 |
Why?
| Follow-Up Studies | 6 | 2021 | 4898 | 0.140 |
Why?
| Blast Crisis | 1 | 2016 | 32 | 0.130 |
Why?
| Carboxypeptidases A | 1 | 2016 | 2 | 0.130 |
Why?
| Retrospective Studies | 10 | 2023 | 14460 | 0.130 |
Why?
| Depression | 2 | 2016 | 1289 | 0.130 |
Why?
| Pediatricians | 1 | 2017 | 132 | 0.130 |
Why?
| Sepsis | 1 | 2022 | 556 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 283 | 0.130 |
Why?
| Mentors | 2 | 2017 | 174 | 0.120 |
Why?
| Osteonecrosis | 1 | 2015 | 24 | 0.120 |
Why?
| Adrenal Cortex Hormones | 1 | 2019 | 518 | 0.120 |
Why?
| Nausea | 1 | 2016 | 108 | 0.120 |
Why?
| Mentoring | 1 | 2017 | 126 | 0.120 |
Why?
| Central Nervous System Neoplasms | 1 | 2017 | 147 | 0.120 |
Why?
| Pancreatitis | 1 | 2016 | 128 | 0.120 |
Why?
| Longitudinal Studies | 7 | 2016 | 2697 | 0.120 |
Why?
| Dexamethasone | 4 | 2021 | 336 | 0.120 |
Why?
| Mutation | 4 | 2022 | 3692 | 0.120 |
Why?
| Monitoring, Physiologic | 1 | 2017 | 267 | 0.120 |
Why?
| Fusion Proteins, bcr-abl | 2 | 2016 | 63 | 0.120 |
Why?
| Cyclin-Dependent Kinase Inhibitor p15 | 3 | 1999 | 16 | 0.110 |
Why?
| Cross Infection | 1 | 2016 | 196 | 0.110 |
Why?
| Antigens, CD | 1 | 2017 | 479 | 0.110 |
Why?
| Myeloid-Lymphoid Leukemia Protein | 2 | 2010 | 71 | 0.110 |
Why?
| Bacteremia | 1 | 2016 | 188 | 0.110 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 485 | 0.110 |
Why?
| Flow Cytometry | 1 | 2018 | 1141 | 0.110 |
Why?
| Repressor Proteins | 1 | 1997 | 400 | 0.110 |
Why?
| Pediatrics | 3 | 2021 | 1061 | 0.110 |
Why?
| Immunotherapy | 1 | 2018 | 585 | 0.110 |
Why?
| DNA-Binding Proteins | 2 | 1998 | 1415 | 0.110 |
Why?
| Life Change Events | 1 | 2014 | 148 | 0.110 |
Why?
| Histone-Lysine N-Methyltransferase | 2 | 2010 | 125 | 0.110 |
Why?
| Chromosomes, Human, Pair 21 | 1 | 2013 | 42 | 0.110 |
Why?
| Venous Thromboembolism | 1 | 2017 | 274 | 0.100 |
Why?
| Quality Improvement | 1 | 2021 | 1100 | 0.100 |
Why?
| Transcription Factors | 2 | 1998 | 1631 | 0.100 |
Why?
| Leukemia, Megakaryoblastic, Acute | 1 | 2012 | 10 | 0.100 |
Why?
| Self Report | 1 | 2017 | 801 | 0.100 |
Why?
| Karyotyping | 3 | 2019 | 107 | 0.100 |
Why?
| Myeloproliferative Disorders | 1 | 2012 | 26 | 0.100 |
Why?
| Contraindications | 1 | 2012 | 88 | 0.100 |
Why?
| Arabinonucleosides | 1 | 2011 | 8 | 0.100 |
Why?
| Adenine Nucleotides | 1 | 2011 | 22 | 0.100 |
Why?
| Cohort Studies | 5 | 2021 | 5369 | 0.090 |
Why?
| Antibodies, Monoclonal | 1 | 2018 | 1355 | 0.090 |
Why?
| Prostatic Neoplasms | 2 | 2009 | 1010 | 0.090 |
Why?
| Chromosomes, Human, Pair 10 | 1 | 2010 | 18 | 0.090 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2010 | 28 | 0.090 |
Why?
| Pain | 1 | 2016 | 756 | 0.080 |
Why?
| Multivariate Analysis | 4 | 2015 | 1494 | 0.080 |
Why?
| T-Lymphocytes | 1 | 2018 | 1922 | 0.080 |
Why?
| Parents | 2 | 2016 | 1306 | 0.080 |
Why?
| Age Factors | 8 | 2019 | 3117 | 0.080 |
Why?
| Prostatectomy | 1 | 2009 | 105 | 0.080 |
Why?
| Bloom Syndrome | 1 | 1988 | 1 | 0.080 |
Why?
| Neoplasm Metastasis | 1 | 2011 | 608 | 0.080 |
Why?
| Gene Expression Regulation, Leukemic | 2 | 2016 | 50 | 0.070 |
Why?
| Juxtaglomerular Apparatus | 1 | 2007 | 1 | 0.070 |
Why?
| Risk Assessment | 4 | 2024 | 3256 | 0.070 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 1019 | 0.070 |
Why?
| Blood Coagulation | 1 | 2008 | 226 | 0.070 |
Why?
| Drug Administration Schedule | 2 | 2017 | 757 | 0.070 |
Why?
| Surveys and Questionnaires | 4 | 2024 | 5346 | 0.060 |
Why?
| Clinical Trials as Topic | 2 | 2024 | 998 | 0.060 |
Why?
| Stress, Psychological | 1 | 2014 | 1058 | 0.060 |
Why?
| Methotrexate | 2 | 2017 | 249 | 0.060 |
Why?
| Remission Induction | 2 | 2019 | 269 | 0.060 |
Why?
| Drug Monitoring | 2 | 2017 | 184 | 0.060 |
Why?
| Case-Control Studies | 3 | 2024 | 3326 | 0.060 |
Why?
| Acute Disease | 2 | 2019 | 968 | 0.060 |
Why?
| Selection Bias | 1 | 2024 | 37 | 0.060 |
Why?
| Personal Satisfaction | 2 | 2017 | 199 | 0.050 |
Why?
| Administration, Oral | 2 | 2017 | 757 | 0.050 |
Why?
| Kidney Neoplasms | 1 | 2007 | 349 | 0.050 |
Why?
| Genetic Variation | 1 | 1988 | 934 | 0.050 |
Why?
| Risk | 5 | 2023 | 852 | 0.050 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2020 | 1358 | 0.050 |
Why?
| Disease Progression | 2 | 2021 | 2603 | 0.050 |
Why?
| Proto-Oncogene Proteins c-cbl | 1 | 2022 | 11 | 0.050 |
Why?
| Incidence | 2 | 2019 | 2619 | 0.050 |
Why?
| Transcriptome | 2 | 2019 | 881 | 0.050 |
Why?
| Exome | 1 | 2022 | 220 | 0.050 |
Why?
| Menorrhagia | 1 | 2001 | 20 | 0.050 |
Why?
| Drug Therapy | 1 | 2021 | 76 | 0.050 |
Why?
| Diarrhea | 2 | 1999 | 177 | 0.040 |
Why?
| Bone Marrow | 1 | 2022 | 267 | 0.040 |
Why?
| Endocrine Glands | 1 | 1979 | 15 | 0.040 |
Why?
| Blood Cell Count | 1 | 1999 | 54 | 0.040 |
Why?
| Chromosomes, Human | 1 | 2019 | 41 | 0.040 |
Why?
| Viral Load | 1 | 2021 | 450 | 0.040 |
Why?
| Azacitidine | 1 | 2020 | 140 | 0.040 |
Why?
| Loss of Heterozygosity | 1 | 1999 | 46 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2019 | 34 | 0.040 |
Why?
| Genome-Wide Association Study | 2 | 2016 | 1337 | 0.040 |
Why?
| Mosaicism | 1 | 2019 | 71 | 0.040 |
Why?
| Disinfectants | 1 | 1999 | 35 | 0.040 |
Why?
| Sequence Deletion | 1 | 1999 | 179 | 0.040 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 215 | 0.040 |
Why?
| Infant, Newborn | 4 | 2019 | 5687 | 0.040 |
Why?
| National Cancer Institute (U.S.) | 1 | 2018 | 43 | 0.040 |
Why?
| Chromosomes | 1 | 2019 | 101 | 0.040 |
Why?
| Interviews as Topic | 1 | 2021 | 705 | 0.040 |
Why?
| Hypertension | 1 | 2007 | 1238 | 0.040 |
Why?
| Overweight | 1 | 2023 | 525 | 0.040 |
Why?
| United States | 4 | 2021 | 13876 | 0.040 |
Why?
| Escherichia coli O157 | 1 | 1998 | 30 | 0.040 |
Why?
| Methylation | 1 | 1998 | 227 | 0.040 |
Why?
| Community Participation | 1 | 1999 | 124 | 0.040 |
Why?
| Genetic Predisposition to Disease | 2 | 2017 | 2266 | 0.040 |
Why?
| Erythrocyte Count | 1 | 2017 | 21 | 0.040 |
Why?
| Glucose | 1 | 2023 | 983 | 0.040 |
Why?
| Biopsy | 1 | 2021 | 1085 | 0.040 |
Why?
| Escherichia coli Infections | 1 | 1998 | 106 | 0.040 |
Why?
| Public Health Surveillance | 1 | 2017 | 67 | 0.040 |
Why?
| Injections, Intramuscular | 1 | 2017 | 117 | 0.040 |
Why?
| Food-Drug Interactions | 1 | 2017 | 8 | 0.040 |
Why?
| Leucovorin | 1 | 2017 | 68 | 0.030 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 1997 | 53 | 0.030 |
Why?
| Career Mobility | 1 | 2017 | 68 | 0.030 |
Why?
| Family | 1 | 2021 | 642 | 0.030 |
Why?
| Feasibility Studies | 1 | 2021 | 860 | 0.030 |
Why?
| Cranial Irradiation | 1 | 2017 | 68 | 0.030 |
Why?
| Water Purification | 1 | 1999 | 146 | 0.030 |
Why?
| Hemorrhage | 1 | 2001 | 644 | 0.030 |
Why?
| Dairy Products | 1 | 2017 | 36 | 0.030 |
Why?
| Cerebrospinal Fluid | 1 | 2017 | 89 | 0.030 |
Why?
| MEF2 Transcription Factors | 1 | 2016 | 62 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2017 | 384 | 0.030 |
Why?
| Sulfonamides | 1 | 2020 | 500 | 0.030 |
Why?
| NIH 3T3 Cells | 1 | 2016 | 141 | 0.030 |
Why?
| Luciferases | 1 | 2016 | 147 | 0.030 |
Why?
| Leukocyte Count | 1 | 2017 | 327 | 0.030 |
Why?
| Methyltransferases | 1 | 2017 | 69 | 0.030 |
Why?
| Methyl Ethers | 1 | 1996 | 8 | 0.030 |
Why?
| Ethers | 1 | 1996 | 16 | 0.030 |
Why?
| Anesthetics, Inhalation | 1 | 1996 | 17 | 0.030 |
Why?
| Bone Morphogenetic Protein 7 | 1 | 2015 | 9 | 0.030 |
Why?
| Fluorides | 1 | 1996 | 49 | 0.030 |
Why?
| Breast Neoplasms | 5 | 1979 | 2139 | 0.030 |
Why?
| Middle Aged | 10 | 2019 | 30893 | 0.030 |
Why?
| Cytarabine | 1 | 2016 | 55 | 0.030 |
Why?
| Health Education | 1 | 1999 | 331 | 0.030 |
Why?
| Genotype | 3 | 2017 | 1831 | 0.030 |
Why?
| Severity of Illness Index | 2 | 2017 | 2736 | 0.030 |
Why?
| Disease Management | 1 | 2019 | 588 | 0.030 |
Why?
| Alternative Splicing | 1 | 2017 | 218 | 0.030 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2016 | 206 | 0.030 |
Why?
| Intensive Care Units, Pediatric | 1 | 2016 | 191 | 0.030 |
Why?
| Qualitative Research | 1 | 2021 | 1205 | 0.030 |
Why?
| Homeodomain Proteins | 1 | 1998 | 487 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 1999 | 1199 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 681 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 428 | 0.030 |
Why?
| Biomarkers, Tumor | 1 | 2021 | 1182 | 0.030 |
Why?
| DNA Methylation | 1 | 1999 | 604 | 0.030 |
Why?
| Aged | 9 | 2019 | 21971 | 0.030 |
Why?
| Algorithms | 1 | 2021 | 1616 | 0.030 |
Why?
| Psychomotor Agitation | 1 | 2014 | 65 | 0.030 |
Why?
| Behavior | 1 | 2014 | 91 | 0.030 |
Why?
| Marriage | 1 | 2014 | 113 | 0.030 |
Why?
| Demography | 1 | 2014 | 277 | 0.030 |
Why?
| Income | 1 | 2014 | 189 | 0.030 |
Why?
| Blood Glucose | 1 | 2023 | 2092 | 0.030 |
Why?
| Base Sequence | 1 | 2016 | 2134 | 0.030 |
Why?
| Odds Ratio | 1 | 2015 | 1022 | 0.020 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2013 | 313 | 0.020 |
Why?
| Aggression | 1 | 2014 | 196 | 0.020 |
Why?
| Nucleoside Transport Proteins | 1 | 2011 | 4 | 0.020 |
Why?
| Time Factors | 2 | 2015 | 6503 | 0.020 |
Why?
| Regression Analysis | 1 | 2014 | 983 | 0.020 |
Why?
| Erythrocytes | 1 | 2017 | 670 | 0.020 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2011 | 69 | 0.020 |
Why?
| Escherichia coli | 1 | 2015 | 770 | 0.020 |
Why?
| Mice | 2 | 2019 | 16579 | 0.020 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 186 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 1265 | 0.020 |
Why?
| Logistic Models | 1 | 2015 | 1975 | 0.020 |
Why?
| Bacteria | 1 | 2016 | 811 | 0.020 |
Why?
| Obesity | 1 | 2023 | 2860 | 0.020 |
Why?
| Prevalence | 1 | 2016 | 2549 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 857 | 0.020 |
Why?
| Emotions | 1 | 2014 | 533 | 0.020 |
Why?
| Sister Chromatid Exchange | 1 | 1988 | 4 | 0.020 |
Why?
| Genetic Complementation Test | 1 | 1988 | 63 | 0.020 |
Why?
| Cell Fusion | 1 | 1988 | 51 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 5257 | 0.020 |
Why?
| Protein C | 1 | 2008 | 39 | 0.020 |
Why?
| Water Microbiology | 2 | 1999 | 85 | 0.020 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 83 | 0.020 |
Why?
| Antithrombins | 1 | 2008 | 53 | 0.020 |
Why?
| Fibrinogen | 1 | 2008 | 158 | 0.020 |
Why?
| Genetic Markers | 1 | 1988 | 339 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 2008 | 396 | 0.020 |
Why?
| Biopsy, Needle | 1 | 2007 | 189 | 0.020 |
Why?
| Renin-Angiotensin System | 1 | 2007 | 80 | 0.020 |
Why?
| Rare Diseases | 1 | 2007 | 103 | 0.020 |
Why?
| Blood Pressure Determination | 1 | 2007 | 150 | 0.020 |
Why?
| Biomarkers | 1 | 2017 | 3881 | 0.020 |
Why?
| Nephrectomy | 1 | 2007 | 159 | 0.020 |
Why?
| Animals | 2 | 2019 | 34501 | 0.020 |
Why?
| RNA, Messenger | 1 | 2011 | 2674 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2007 | 1669 | 0.010 |
Why?
| Cell Line | 1 | 1988 | 2731 | 0.010 |
Why?
| Anemia, Hypochromic | 1 | 2001 | 4 | 0.010 |
Why?
| Blood Platelet Disorders | 1 | 2001 | 10 | 0.010 |
Why?
| von Willebrand Diseases | 1 | 2001 | 17 | 0.010 |
Why?
| Estriol | 1 | 1979 | 7 | 0.010 |
Why?
| Estrone | 1 | 1979 | 37 | 0.010 |
Why?
| Menstruation | 1 | 1979 | 44 | 0.010 |
Why?
| Prolactin | 1 | 1979 | 97 | 0.010 |
Why?
| Thrombocytopenia | 1 | 2001 | 182 | 0.010 |
Why?
| Bolivia | 1 | 1999 | 63 | 0.010 |
Why?
| Luteinizing Hormone | 1 | 1979 | 178 | 0.010 |
Why?
| Follicle Stimulating Hormone | 1 | 1979 | 239 | 0.010 |
Why?
| Restaurants | 1 | 1998 | 19 | 0.010 |
Why?
| Swimming | 1 | 1998 | 47 | 0.010 |
Why?
| Food Handling | 1 | 1998 | 60 | 0.010 |
Why?
| Progesterone | 1 | 1979 | 244 | 0.010 |
Why?
| Disease Transmission, Infectious | 1 | 1998 | 57 | 0.010 |
Why?
| Water Supply | 1 | 1998 | 74 | 0.010 |
Why?
| Meat | 1 | 1998 | 93 | 0.010 |
Why?
| Halothane | 1 | 1996 | 6 | 0.010 |
Why?
| Estradiol | 1 | 1979 | 497 | 0.010 |
Why?
| Analysis of Variance | 1 | 1999 | 1271 | 0.010 |
Why?
| Population Surveillance | 1 | 1999 | 427 | 0.010 |
Why?
| Feces | 1 | 1998 | 432 | 0.010 |
Why?
| Ovarian Neoplasms | 1 | 1978 | 489 | 0.010 |
Why?
| Pedigree | 3 | 1978 | 485 | 0.010 |
Why?
| Kidney | 1 | 1996 | 1305 | 0.000 |
Why?
| Aged, 80 and over | 1 | 1999 | 7040 | 0.000 |
Why?
| Nebraska | 2 | 1976 | 9 | 0.000 |
Why?
| New York | 2 | 1976 | 123 | 0.000 |
Why?
| Genes | 1 | 1978 | 226 | 0.000 |
Why?
| Genetic Linkage | 1 | 1978 | 299 | 0.000 |
Why?
| Oncogenic Viruses | 1 | 1976 | 3 | 0.000 |
Why?
| Apocrine Glands | 1 | 1976 | 4 | 0.000 |
Why?
| Genetic Techniques | 1 | 1976 | 64 | 0.000 |
Why?
| Pheochromocytoma | 1 | 1976 | 57 | 0.000 |
Why?
| Klinefelter Syndrome | 1 | 1976 | 56 | 0.000 |
Why?
| Syndrome | 1 | 1976 | 335 | 0.000 |
Why?
| Statistics as Topic | 1 | 1976 | 304 | 0.000 |
Why?
| Pregnancy | 2 | 1978 | 6297 | 0.000 |
Why?
| HLA Antigens | 1 | 1976 | 235 | 0.000 |
Why?
| Abnormalities, Multiple | 1 | 1976 | 178 | 0.000 |
Why?
| Skin Diseases | 1 | 1976 | 142 | 0.000 |
Why?
| Sarcoma | 1 | 1976 | 177 | 0.000 |
Why?
| Sex Factors | 1 | 1978 | 1949 | 0.000 |
Why?
| Thyroid Neoplasms | 1 | 1976 | 311 | 0.000 |
Why?
| Neoplasms | 2 | 1976 | 2465 | 0.000 |
Why?
| Melanoma | 1 | 1976 | 749 | 0.000 |
Why?
| Registries | 1 | 1976 | 1878 | 0.000 |
Why?
| Phenotype | 1 | 1976 | 3050 | 0.000 |
Why?
| Brain Neoplasms | 1 | 1976 | 1149 | 0.000 |
Why?
|
|
Maloney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|